Analysts Set Integra LifeSciences Holdings Co. (NASDAQ:IART) Price Target at $36.80

Integra LifeSciences Holdings Co. (NASDAQ:IARTGet Free Report) has been assigned an average recommendation of “Hold” from the ten brokerages that are presently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating on the company. The average 12 month price target among brokers that have covered the stock in the last year is $35.00.

IART has been the subject of several recent research reports. Morgan Stanley cut their target price on shares of Integra LifeSciences from $37.00 to $24.00 and set an “underweight” rating for the company in a research report on Tuesday, May 7th. Oppenheimer lowered Integra LifeSciences from an “outperform” rating to a “market perform” rating in a research note on Tuesday, May 7th. Truist Financial lowered their target price on Integra LifeSciences from $37.00 to $25.00 and set a “hold” rating on the stock in a research report on Tuesday, May 7th. StockNews.com cut Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Monday, May 13th. Finally, Bank of America lowered their price objective on Integra LifeSciences from $42.00 to $26.00 and set an “underperform” rating on the stock in a research report on Tuesday, May 7th.

Read Our Latest Stock Report on IART

Integra LifeSciences Price Performance

Shares of IART opened at $28.51 on Tuesday. The firm has a fifty day simple moving average of $30.66 and a two-hundred day simple moving average of $37.42. The firm has a market cap of $2.25 billion, a PE ratio of 57.02, a P/E/G ratio of 0.99 and a beta of 1.17. The company has a current ratio of 4.68, a quick ratio of 3.35 and a debt-to-equity ratio of 1.15. Integra LifeSciences has a 1-year low of $22.36 and a 1-year high of $46.75.

Integra LifeSciences (NASDAQ:IARTGet Free Report) last posted its earnings results on Monday, May 6th. The life sciences company reported $0.55 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.55. The company had revenue of $368.90 million for the quarter, compared to the consensus estimate of $361.96 million. Integra LifeSciences had a return on equity of 14.27% and a net margin of 2.63%. Integra LifeSciences’s revenue was down 3.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.74 earnings per share. On average, equities analysts anticipate that Integra LifeSciences will post 3.03 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Allspring Global Investments Holdings LLC lifted its holdings in shares of Integra LifeSciences by 451.9% in the third quarter. Allspring Global Investments Holdings LLC now owns 70,827 shares of the life sciences company’s stock worth $2,705,000 after buying an additional 57,993 shares in the last quarter. Panagora Asset Management Inc. purchased a new stake in Integra LifeSciences in the 3rd quarter worth $223,000. Teacher Retirement System of Texas boosted its holdings in shares of Integra LifeSciences by 21.9% during the 3rd quarter. Teacher Retirement System of Texas now owns 27,960 shares of the life sciences company’s stock valued at $1,068,000 after purchasing an additional 5,025 shares during the last quarter. California Public Employees Retirement System grew its position in shares of Integra LifeSciences by 1.0% during the third quarter. California Public Employees Retirement System now owns 141,677 shares of the life sciences company’s stock valued at $5,411,000 after purchasing an additional 1,335 shares in the last quarter. Finally, Victory Capital Management Inc. increased its holdings in shares of Integra LifeSciences by 19.5% in the third quarter. Victory Capital Management Inc. now owns 1,465,115 shares of the life sciences company’s stock worth $55,953,000 after purchasing an additional 238,816 shares during the last quarter. 84.78% of the stock is owned by hedge funds and other institutional investors.

Integra LifeSciences Company Profile

(Get Free Report

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.

Further Reading

Analyst Recommendations for Integra LifeSciences (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.